Spironolactone Fails to Cut Serious Cardiac Events in End-Stage Kidney Disease



(MedPage Today) — Daily treatment with a mineralocorticoid receptor antagonist flopped for reducing serious cardiac events in kidney failure patients on maintenance dialysis, a randomized trial found.
Among over 2,500 patients in the ACHIEVE…



Source link : https://www.medpagetoday.com/meetingcoverage/era/115970

Author :

Publish date : 2025-06-09 16:57:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version